350 related articles for article (PubMed ID: 33654378)
1. The Risks of miRNA Therapeutics: In a Drug Target Perspective.
Zhang S; Cheng Z; Wang Y; Han T
Drug Des Devel Ther; 2021; 15():721-733. PubMed ID: 33654378
[TBL] [Abstract][Full Text] [Related]
2. RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies.
Traber GM; Yu AM
J Pharmacol Exp Ther; 2023 Jan; 384(1):133-154. PubMed ID: 35680378
[TBL] [Abstract][Full Text] [Related]
3. The Growing Class of Novel RNAi Therapeutics.
Traber GM; Yu AM
Mol Pharmacol; 2024 Jun; 106(1):13-20. PubMed ID: 38719476
[TBL] [Abstract][Full Text] [Related]
4. MicroRNAs with Multiple Targets of Immune Checkpoints, as a Potential Sensitizer for Immune Checkpoint Inhibitors in Breast Cancer Treatment.
Zhou H; Jia W; Lu L; Han R
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765782
[TBL] [Abstract][Full Text] [Related]
5. Trials and Tribulations of MicroRNA Therapeutics.
Seyhan AA
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338746
[TBL] [Abstract][Full Text] [Related]
6. MicroRNAs as promising therapeutic agents: A perspective from acupuncture.
Li S; Huang Q; Yang Q; Peng X; Wu Q
Pathol Res Pract; 2023 Aug; 248():154652. PubMed ID: 37406378
[TBL] [Abstract][Full Text] [Related]
7. Leading RNA Interference Therapeutics Part 1: Silencing Hereditary Transthyretin Amyloidosis, with a Focus on Patisiran.
Titze-de-Almeida SS; Brandão PRP; Faber I; Titze-de-Almeida R
Mol Diagn Ther; 2020 Feb; 24(1):49-59. PubMed ID: 31701435
[TBL] [Abstract][Full Text] [Related]
8. Innovative approaches in transforming microRNAs into therapeutic tools.
Samad AFA; Kamaroddin MF
Wiley Interdiscip Rev RNA; 2023 Jan; 14(1):e1768. PubMed ID: 36437633
[TBL] [Abstract][Full Text] [Related]
9. Identifying Cleaved and Noncleaved Targets of Small Interfering RNAs and MicroRNAs in Mammalian Cells by SpyCLIP.
Zhang Y; Teng Y; Xiao W; Xu B; Zhao Y; Li W; Wu L
Mol Ther Nucleic Acids; 2020 Dec; 22():900-909. PubMed ID: 33251041
[TBL] [Abstract][Full Text] [Related]
10. siRNA therapeutics: a clinical reality.
Saw PE; Song EW
Sci China Life Sci; 2020 Apr; 63(4):485-500. PubMed ID: 31054052
[TBL] [Abstract][Full Text] [Related]
11. RNA-targeted therapeutics in cancer clinical trials: Current status and future directions.
Barata P; Sood AK; Hong DS
Cancer Treat Rev; 2016 Nov; 50():35-47. PubMed ID: 27612280
[TBL] [Abstract][Full Text] [Related]
12. Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics.
Kulkarni JA; Witzigmann D; Chen S; Cullis PR; van der Meel R
Acc Chem Res; 2019 Sep; 52(9):2435-2444. PubMed ID: 31397996
[TBL] [Abstract][Full Text] [Related]
13. Development of siRNA Therapeutics for the Treatment of Liver Diseases.
Holm A; Løvendorf MB; Kauppinen S
Methods Mol Biol; 2021; 2282():57-75. PubMed ID: 33928570
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA therapeutics: the emerging anticancer strategies.
Jain CK; Gupta A; Dogra N; Kumar VS; Wadhwa G; Sharma SK
Recent Pat Anticancer Drug Discov; 2014; 9(3):286-96. PubMed ID: 24605908
[TBL] [Abstract][Full Text] [Related]
15. Development of miRNA-based therapeutic approaches for cancer patients.
Takahashi RU; Prieto-Vila M; Kohama I; Ochiya T
Cancer Sci; 2019 Apr; 110(4):1140-1147. PubMed ID: 30729639
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-based therapeutics for cancer.
Wang V; Wu W
BioDrugs; 2009; 23(1):15-23. PubMed ID: 19344188
[TBL] [Abstract][Full Text] [Related]
17. Leading RNA Interference Therapeutics Part 2: Silencing Delta-Aminolevulinic Acid Synthase 1, with a Focus on Givosiran.
de Paula Brandão PR; Titze-de-Almeida SS; Titze-de-Almeida R
Mol Diagn Ther; 2020 Feb; 24(1):61-68. PubMed ID: 31792921
[TBL] [Abstract][Full Text] [Related]
18. Development of novel cardiovascular therapeutics from small regulatory RNA molecules--an outline of key requirements.
Poller W; Fechner H
Curr Pharm Des; 2010; 16(20):2252-68. PubMed ID: 20459390
[TBL] [Abstract][Full Text] [Related]
19. The Race of 10 Synthetic RNAi-Based Drugs to the Pharmaceutical Market.
Titze-de-Almeida R; David C; Titze-de-Almeida SS
Pharm Res; 2017 Jul; 34(7):1339-1363. PubMed ID: 28389707
[TBL] [Abstract][Full Text] [Related]
20. RNAi-based drug discovery and its application to therapeutics.
Hokaiwado N; Takeshita F; Banas A; Ochiya T
IDrugs; 2008 Apr; 11(4):274-8. PubMed ID: 18379962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
